Novel Markers for the Treatment and Diagnosis of Chronic Lumphocytic Leukemia (CLL)
- Technology Benefits
- Technology can be used in the form of a kit for CLL diagnostics.Potential CLL therapy by inhibiting PDE7B, resulting in apoptosis of CLL lymphocytes.
- Detailed Technology Description
- Researchers at UC San Diego have developed a novel technology to diagnose CLL. They have demonstrated an enhanced expression of phosphodiesterase isoform 7B (PDE7B) in lymphocytes of CLL patients. Thus PDE7B can be used as a biomarker for diagnosis and prognosis of CLL.Features of this technology include: PDE7B mRNA and protein levels are increased in CLL patients to up to 70- and 90-fold, respectively.Potential therapeutic agents comprise PDE7B inhibitors, antagonists, and antibodies.
- Supplementary Information
- Patent Number: US7846664B2
Application Number: US200896628A
Inventor: Insel, Paul A. | Zhang, Lingzhi | Murray, Fiona | Kanter, Joan R. | Kipps, Thomas | Rassenti, Laura
Priority Date: 7 Dec 2005
Priority Number: US7846664B2
Application Date: 9 Jun 2008
Publication Date: 7 Dec 2010
IPC Current: C12Q000168 | C07H002102 | C07H002104
US Class: 43500612 | 435006 | 5360231 | 53602431 | 53602433
Assignee Applicant: The Regents of the University of California
Title: Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
Usefulness: Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
Summary: The method and kit are useful for diagnosing CLL. The method and composition are useful for treating CLL.
Novelty: Diagnosing chronic lymphocytic leukemia (CLL) comprises comparing the patient's expression level to the expression level of the isoform of PDE associated with CLL in a normal subject
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application No.
- 7846664
- Others
-
State Of Development
- Increase in PDE7B levels has been detected in CLL patients.
- This technology is offered exclusively or nonexclusively in the U.S.
Related Materials
- Zhang, L., et al., Cyclic Nucleotide Phosphodiesterase Profiling Reveals Increased Expression of Phosphodiesterase 7B in Chronic Lymphocytic Leukemia. Proc Natl Acad Sci USA, 2008. 105(49): p. 19532-7.
- News release at http://ucsdnews.ucsd.edu/newsrel/health/04-09AACR.asp
- Zhang L, Murray F, Rassenti LZ, Pu M, Kelly C, Kanter JR, Greaves A, Messer K, Kipps TJ, Insel PA. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer. 2011 Sep 1;129(5):1162-9. doi: 10.1002/ijc.25785. Epub 2011 Feb 11.
Intellectual Property Info
Patent application (No. 12/960,955) allowance granted.
Tech ID/UC Case
19546/2006-052-0
Related Cases
2006-052-0
- *Abstract
-
Therapeutic options for patients with chronic lymphocytic leukemia (CLL) are limited, and in most cases ineffective, or with a limited period of effectiveness. Relapse of the disease often occurs and patients acquire resistance, not only to the drug used, but to other drugs as well. Moreover, a specific marker for CLL does not exist on the market today. Patients ‘wait and see’ if the symptoms progress in the early stages of the disease before a diagnosis is made. Instead of being treated immediately, the disease could lurk for years.
- *IP Issue Date
- Dec 7, 2010
- *Principal Investigator
-
Name: Paul Insel
Department:
Name: Joan Kanter
Department:
Name: Thomas Kipps
Department:
Name: Fiona Murray
Department:
Name: Laura Rassenti
Department:
Name: Lingzhi Zhang
Department:
- Country/Region
- USA
For more information, please click Here
